Frederick Bartholomew, MD
Dermatology · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bartholomew’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A172548 · Current
Licensed to practise in California · since 2021 · expires 2027-05-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$150,906
Medicare paid this office $150,906 for 417 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 280 | $55,842 | $109 |
| New patient visit (45+ min) | 179 | $22,431 | $125 |
| Destruction of skin growth, 1-14 growths | 136 | $19,587 | $111 |
| Biopsy of related skin growth, first growth | 77 | $8,467 | $92 |
| Destruction of precancer skin growth, 1 growth | 130 | $7,383 | $46 |
See all 9 services
| Return visit (30+ min) | 280 | $55,842 | $109 |
| New patient visit (45+ min) | 179 | $22,431 | $125 |
| Destruction of skin growth, 1-14 growths | 136 | $19,587 | $111 |
| Biopsy of related skin growth, first growth | 77 | $8,467 | $92 |
| Destruction of precancer skin growth, 1 growth | 130 | $7,383 | $46 |
| Destruction of precancer skin growth, 15 or more growths | 34 | $7,006 | $163 |
| Destruction of precancer skin growth, 2-14 growths | 105 | $3,924 | $7 |
| Short return visit (20+ min) | 12 | $1,248 | $83 |
| New patient visit (30+ min) | 18 | $1,211 | $67 |
Procedures Medicare counted
| Removal of skin lesions | 816 | More than 91% of doctors who do this |
| Removal or shaving of skin growth | 60 | More than 81% of doctors who do this |
| Skin biopsy | 127 | More than 79% of doctors who do this |
Who their Medicare patients are
417 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 13% · Women 51% · Also on Medicaid 6% · Health risk score 0.99. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 61% · Coronary heart disease 21% · Diabetes 19% · Chronic kidney disease 18% · Cancer 15% · Atrial fibrillation 14% · Depression 12% · Heart failure 8% · COPD 6% · Dementia 5%.
The office billed $566,286, Medicare allowed $208,996 and paid $150,906; for 2,059 services of 29 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 417 | 2,059 | 75 | 0.99 | $566,286 | $150,906 |
| 2023 | 368 | 1,559 | 75 | 0.93 | $381,990 | $107,361 |
| 2022 | 140 | 507 | 74 | 0.85 | $86,898 | $30,453 |
| 2021 | 36 | 113 | 72 | 0.77 | $12,475 | $6,261 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 191 | $33,786 | $113 |
| New patient visit (45+ min) | 201 | $25,452 | $127 |
| Destruction of skin growth, 1-14 growths | 110 | $13,939 | $111 |
| Biopsy of related skin growth, first growth | 96 | $8,750 | $86 |
| Destruction of precancer skin growth, 1 growth | 87 | $5,668 | $50 |
| New patient visit (30+ min) | 42 | $3,614 | $86 |
| Destruction of precancer skin growth, 2-14 growths | 64 | $3,232 | $7 |
| Destruction of precancer skin growth, 15 or more growths | 16 | $3,135 | $165 |
| Short return visit (20+ min) | 29 | $2,390 | $72 |
| Biopsy of related skin growth, each additional growth | 18 | $973 | $51 |
2022: 9 services
| New patient visit (45+ min) | 40 | $5,477 | $137 |
| Return visit (30+ min) | 35 | $4,648 | $106 |
| Short return visit (20+ min) | 40 | $3,344 | $70 |
| Destruction of skin growth, 1-14 growths | 27 | $3,286 | $103 |
| New patient visit (30+ min) | 26 | $2,390 | $92 |
| Biopsy of related skin growth, first growth | 24 | $2,241 | $90 |
| Destruction of precancer skin growth, 1 growth | 40 | $2,162 | $47 |
| Destruction of precancer skin growth, 2-14 growths | 30 | $1,206 | $6 |
| Short return visit | 12 | $537 | $41 |
2021: 1 service
| Short return visit (20+ min) | 17 | $1,457 | $77 |
Medicaid work
$3,908 in 2024
Medicaid paid $3,908 for 45 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 45 | $3,908 |
| 2024 | 45 | 1 | 19 | $3,908 |
| 2023 | 77 | 1 | 18 | $2,428 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 77 | $2,428 |
Drugs they prescribed that Part D paid
$182,013
Pharmacies billed $182,013 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,171) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
1,113 generic and 58 brand-name prescriptions · $182,013 in drug cost · 40 antibiotic prescriptions to 32 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Cosentyx Sensoready (2 Pens) | 13 | $95,160 | $7,320 |
| Fluocinonide | 133 | $5,131 | $39 |
| Ketoconazole | 257 | $4,600 | $18 |
| Metronidazole | 103 | $4,461 | $43 |
| Pimecrolimus | 13 | $3,043 | $234 |
See all 19 drugs
| Cosentyx Sensoready (2 Pens) | 13 | $95,160 | $7,320 |
| Fluocinonide | 133 | $5,131 | $39 |
| Ketoconazole | 257 | $4,600 | $18 |
| Metronidazole | 103 | $4,461 | $43 |
| Pimecrolimus | 13 | $3,043 | $234 |
| Desonide | 88 | $2,950 | $34 |
| Clobetasol Propionate | 71 | $2,661 | $37 |
| Clobetasol Emollient | 22 | $1,906 | $87 |
| Tacrolimus | 25 | $1,852 | $74 |
| Fluorouracil | 22 | $1,646 | $75 |
| Clindamycin Phosphate | 34 | $1,404 | $41 |
| Ciclopirox | 38 | $1,118 | $29 |
| Tretinoin | 24 | $1,057 | $44 |
| Mometasone Furoate | 59 | $936 | $16 |
| Doxycycline Hyclate | 39 | $698 | $18 |
| Halobetasol Propionate | 12 | $668 | $56 |
| Triamcinolone Acetonide | 101 | $658 | $7 |
| Mupirocin | 19 | $155 | $8 |
| Hydrocortisone | 11 | $52 | $5 |
Year by year
| 2024 | 1,171 | 457 | 0% (0) | 5% | $182,013 |
| 2023 | 903 | 340 | 0% (0) | 10% | $374,120 |
| 2022 | 305 | 159 | 0% (0) | 6% | $85,039 |
| 2021 | 218 | 104 | 0% (0) | 7% | $44,808 |
| 2020 | 86 | 39 | 0% (0) | None | $7,985 |
| 2019 | 257 | 87 | 0% (0) | 18% | $64,707 |
| 2018 | 121 | 47 | 0% (0) | 14% | $17,423 |
| 2017 | 227 | 87 | None | 16% | $49,348 |
| 2016 | 31 | 19 | None | None | $662 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Cosentyx Sensoready | 26 | $297,776 | $11,453 |
| Fluocinonide | 107 | $6,361 | $59 |
| Ketoconazole | 212 | $5,611 | $26 |
| Clobetasol Propionate | 78 | $4,844 | $62 |
| Metronidazole | 64 | $4,116 | $64 |
| Desonide | 58 | $2,718 | $47 |
| Tacrolimus | 12 | $2,314 | $193 |
| Clobetasol Emollient | 21 | $2,043 | $97 |
| Clindamycin Phosphate | 38 | $1,826 | $48 |
| Tretinoin | 14 | $1,267 | $91 |
| Ciclopirox | 31 | $1,172 | $38 |
| Triamcinolone Acetonide | 74 | $702 | $9 |
| Mometasone Furoate | 27 | $659 | $24 |
| Doxycycline Hyclate | 24 | $609 | $25 |
| Mupirocin | 23 | $280 | $12 |
| Hydrocortisone | 24 | $142 | $6 |
2022: 6 drugs
| Ketoconazole | 82 | $1,879 | $23 |
| Clobetasol Propionate | 24 | $1,160 | $48 |
| Fluocinolone Acetonide | 11 | $534 | $49 |
| Triamcinolone Acetonide | 43 | $409 | $10 |
| Mupirocin | 28 | $252 | $9 |
| Hydrocortisone | 14 | $101 | $7 |
2021: 5 drugs
| Ketoconazole | 61 | $1,258 | $21 |
| Clobetasol Propionate | 14 | $788 | $56 |
| Triamcinolone Acetonide | 43 | $369 | $9 |
| Mupirocin | 20 | $140 | $7 |
| Hydrocortisone | 13 | $98 | $8 |
2020: 2 drugs
| Ketoconazole | 38 | $1,013 | $27 |
| Triamcinolone Acetonide | 18 | $167 | $9 |
2019: 4 drugs
| Metronidazole | 13 | $1,894 | $146 |
| Ketoconazole | 71 | $1,733 | $24 |
| Clindamycin Phosphate | 16 | $1,412 | $88 |
| Triamcinolone Acetonide | 39 | $356 | $9 |
2018: 2 drugs
| Ketoconazole | 47 | $1,587 | $34 |
| Triamcinolone Acetonide | 17 | $166 | $10 |
2017: 3 drugs
| Calcipotriene | 12 | $5,852 | $488 |
| Ketoconazole | 31 | $1,245 | $40 |
| Triamcinolone Acetonide | 32 | $367 | $11 |
Money from drug and device companies
$217 in 2025
| 2025 | 4 | 8 | None | $217 |
| 2024 | 1 | 1 | None | $31 |
| 2022 | 2 | 3 | None | $54 |
| 2021 | 3 | 7 | None | $248 |
| 2020 | 1 | 1 | None | $17 |
| 2019 | 1 | 1 | None | $18 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Arcutis Biotherapeutics | Zoryve | $146 | 5 payments
|
| Lilly USA | Taltz | $32 | 1 payment
|
| Abbvie | Skyrizi | $20 | 1 payment
|
| Cipher Pharmaceuticals US | Natroba | $19 | 1 payment
|
See all 8 published payments
| Cipher Pharmaceuticals US | Meals · 2025-12-01 | Natroba | $19 |
| Arcutis Biotherapeutics | Meals · 2025-12-01 | Zoryve | $14 |
| Arcutis Biotherapeutics | Meals · 2025-10-31 | Zoryve | $8 |
| Arcutis Biotherapeutics | Meals · 2025-10-22 | Zoryve | $25 |
| Arcutis Biotherapeutics | Meals · 2025-09-05 | Zoryve | $94 |
| Lilly USA | Meals · 2025-08-18 | Taltz | $32 |
| Abbvie | Meals · 2025-04-12 | Skyrizi | $20 |
| Arcutis Biotherapeutics | Meals · 2025-02-28 | Zoryve | $6 |
See earlier years (2024, 2022, 2021, 2020, 2019)
2024: $31
| Abbvie | Skyrizi | $31 | 1 payment
|
2022: $54
| Pfizer | Cibinqo | $30 | 2 payments
|
| LEO Pharma | Adbry | $24 | 1 payment
|
2021: $248
| AbbVie | Skyrizi | $182 | 4 payments
|
| Novartis Pharmaceuticals | Cosentyx | $46 | 2 payments
|
| Incyte | Opzelura | $20 | 1 payment
|
2020: $17
| AbbVie | Skyrizi | $17 | 1 payment
|
2019: $18
| Allergan | Viberzi | $18 | 1 payment
|
Professional record
- NPI
- 1457702383
- Licence
- CA A172548, MA 267576California A172548: Current · expires 2027-05-31
- Trained
- Stanford University School of Medicine, 2016
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Internal medicine (207R00000X)
- Mailing address
- 1720 El Camino Real Ste 116, Burlingame, CA, 94010
- NPI first listed
- 2016-06-22
- NPI last updated
- 2022-10-13
- NPI record certified
- 2022-10-13
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 330 Mount Auburn St, Cambridge, MA, 02138